



State of play Commission Action Plan to Combat the rising threat from Antimicrobial Resistance: activities in the human sector

Joint Conference on Antimicrobial Resistance: State of play of the 5 year action plan, 11 December 2013

> DG Health and Consumers European Commission John-F. Ryan, Acting Director Public Health



Action plan against the rising threats from antimicrobial resistance (COM (2011) 748) - 17 Nov 2011

5 year action planHolistic approach7 key areas12 concrete actions

DG SANCO

Communication from the Commission to the European Parliament and the Council

Action plan against the rising threats from Antimicrobial Resistance

COM (2011) 748



The 7 areas where action is needed

- **Appropriate use** of antimicrobials (humans and animals)
- **Prevention** microbial infections and their spread
- Development new effective antimicrobials or alternatives for treatment
- Improvement monitoring and surveillance (human and animal medicine)
- Cooperation with international partners to contain the risks of AMR
- Promotion **research** and innovation
- Improvement communication, education and training

Roadmap: http://ec.europa.eu/dgs/health_consumer/docs/road-map-amr_en.pdf 3





A EUROPEAN HEALTH INITIATIVE

Klebsiella pneumoniae: percentage of carbapenem-resistant infections




2009

Source: EARS-Net, 2013

↑ and ↓ indicate a significant increasing or decreasing trend between 2009 and 2012. Trends were calculated with data from laboratories which consistently reported during this period.

EU/EEA, 2009-12







Overview: Actions relating to the Human Sector

- Action no 1: Strengthening the promotion of appropriate use of antimicrobials in human medicines in all Member States
- Action no 4: Strengthen infection prevention and control in healthcare settings
- Action no 6: Develop new effective antimicrobials or alternatives for treatment
- Action no 8: Develop and strengthen multilateral and bilateral commitments for the prevention and control of AMR in all sectors

5

- Action no 9: Strengthen surveillance systems on AMR and antimicrobial consumption in human medicine
- Action no 12: Communication, education and training survey and comparative effectiveness research



Action 1: Appropriate use of antimicrobials in human medicines

1/2
 The EP and Commission decided to finance a Preparatory action to research and document the non-prudent use of antibiotics in human medicines across Europe (start beginning 2014)

Objective:

-identify key factors driving the sales and non- prudent use of antibiotics in human medicines obtained without prescription

-assess level of enforcement of prescription only requirement -document best practices aimed at a more prudent use

-recommend policy options_{DG SANCO}



Action 1: Appropriate use of antimicrobials in human medicines 2/2

"Best use of medicines legislation to bring new antibiotics to patients and combat the resistance problem", EMA conference, 8-11-2013

- Appropriate use of antibiotics is the responsibility of all actors
- Prescription only antibiotics
- Up-to-date and evidence-based product information, reference to official guidance on the appropriate use

DG SANCO



Action 4: Prevention and control of healthcare-associated infection

 First implementation report on the Council recommendation on patient safety including healthcare associated infections
 – adopted 13 November 2012

http://ec.europa.eu/health/patient_safety/docs/council_2009_report_en.pdf

- Second Commission implementation report under preparation (publication mid 2014)
- ECDC point prevalence survey of healthcare associatedinfections (HAI) and antimicrobial use in acute care hospitals published July 2013



Action 6: Bringing new antibiotics to patients

"Best use of medicines legislation to bring new antibiotics to patients and combat the resistance problem", EMA conference, 8-11-2013

Authorisation of new antibacterials -clarity and flexibility of regulatary famework: "fit for purpose" -risk-benefit vs early access

Research and development

DG SANCO



Action 8: International cooperation (human sector)

- WHO \rightarrow bilateral contacts and joint actions/meetings
- Transatlantic Taskforce on Antimicrobial Resistance (TATFAR)
 Progress report (first quarter 2014)
- Bilateral collaboration with other countries:
 - -China → Human/veterinarian symposia March 2013
 - -DG-Sanco- Russian Federation subgroup on communicable diseases



Action 9: Strengthen surveillance systems on AMR and antimicrobial consumption in human medicine

- Sustainability of the European Surveillance system of Antimicrobial Consumption (ESAC) ensured (transfer of ESAC to ECDC completed – ESAC-net)
- 1rst ESAC-net Report published
- 2nd ESAC-net Report (to be published early 2014)
- Addressing the lack of data on AMR and antimicrobial consumption in children: dedicated EU project (ARPEC) ongoing (about to be finalised)



Action 12: Communication

European Antimicrobial Awareness Day (EAAD)

- Holistic approach: participation of Fédération Vétérinaires Européens (FVE) and Standing Committee of European Doctors (CPME)
- Nearly 1,000,000 impressions on Twitter
- Lightbulb video on Euronews \rightarrow 9,405,000 people reached
- European Antimicrobial Awareness Day 2013 ECDC stakeholder event 15 November 2013
 - Overall theme: "Everyone's responsible"
 - Over 40 countries participating, growing into a global event



Action 12: Communication

2nd Eurobarometer Survey on AMR (published 15 Nov 2013)

- designed to allow indication of trends in comparison to the 2009 last survey
- shows a modest positive evolution in EU citizens' use of and knowledge about antibiotics, since the last survey in 2009.
- 35% of respondents say they have taken antibiotics in the past year (a 5% decrease since the 2009 survey).
- 2% fewer people took antibiotics for the flu in 2013 compared with 2009: 18% vs. 20%.

In 2013 more people are aware that antibiotics do not kill viruses than in 2009: 40% vs. 36%.



Discussion: Challenges

- Improve the prudent use of antibiotics (including reduction of over the counter sales)
- > Infection prevention and healthcare settings
- Incentives for new antibiotics new business model



Thank you



DG SANCO